AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.090
+0.030 (2.83%)
Nov 28, 2025, 4:00 PM EST - Market closed
AN2 Therapeutics Employees
AN2 Therapeutics had 22 employees as of December 31, 2024. The number of employees decreased by 19 or -46.34% compared to the previous year.
Employees
22
Change (1Y)
-19
Growth (1Y)
-46.34%
Revenue / Employee
n/a
Profits / Employee
-$1,544,818
Market Cap
29.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | -19 | -46.34% |
| Dec 31, 2023 | 41 | 5 | 13.89% |
| Dec 31, 2022 | 36 | 14 | 63.64% |
| Dec 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANTX News
- 18 days ago - AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 20 days ago - AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Business Wire
- 24 days ago - AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference - Business Wire
- 3 months ago - AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 3 months ago - AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Business Wire
- 4 months ago - AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease - Business Wire
- 5 months ago - AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole - Business Wire
- 6 months ago - AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference - Business Wire